After Celgene (CELG) disclosed the termination of its trial for CC-90002, an IgG4 construct that targets CD47, in acute myeloid leukemia and myelodysplastic syndrome patients, Credit Suisse analyst Martin Auster said the associated selloff in shares of Forty Seven (FTSV) seems premature to him. He does not believe the discontinuation in AML/MDS has a negative read-through to Forty Seven's 5F9 profile to date or its development in other indications, Auster tells investors. The analyst, who keeps an Outperform rating on Forty Seven shares, still sees promising efficacy in NHL providing a strong valuation base with substantial upside potential offered as 5F9 efficacy data matures.